GlassScriptPhysician profile
Flavy Francique
NPI 1952770497
$1,759.43
in general payments reported to CMS, 2019-2025
13 companies · $697 in 2025
The $697 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $380 · 2022: $80.47 · 2023: $13.19 · 2024: $589 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,131 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,131.45 |
| Education | $167.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $326.95 | 2024-2025 | Trodelvy |
| Incyte Corporation | $200.38 | 2024-2025 | Monjuvi |
| Abbvie INC. | $198.42 | 2021-2024 | |
| Tactile Systems Technology INC | $143.88 | 2025 | Nimbl, Flexitouch Plus |
| Genzyme Corporation | $142.64 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.83 | 2025 | |
| Daiichi Sankyo INC. | $121.84 | 2021 | |
| Pharmacosmos Therapeutics INC. | $121.83 | 2025 | Cosela |
| Astellas Pharma US INC | $102.67 | 2024-2025 | Xtandi |
| Karyopharm Therapeutics INC. | $97.47 | 2024 | Xpovio |
| Astrazeneca Pharmaceuticals LP | $94.84 | 2021 | |
| Stemline Therapeutics INC. | $62.66 | 2024 | Orserdu |
| Pfizer INC. | $21.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Flavy Francique listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.